Research
Energy balance
The new user rate of semaglutide (Ozempic ® ) remained stable at approximately 4 per 1000 adult person-years between 2019 and 2021 and then peaked at 10 per 1000 in the first quarter of 2023.
Practitioners should be aware of the increasing trend in semaglutide prescriptions, particularly in 2023.
ModerateSupportsmedium confidence
The new user rate of semaglutide (Ozempic ® ) remained stable at approximately 4 per 1000 adult person-years between 2019 and 2021 and then accelerated, peaking at 10 per 1000 in the first quarter of 2023 after which it declined sharply.
Why this rating
Based on a cross-sectional study design.
Source
Semaglutide (Ozempic®) Use in Denmark 2018 Through 2023 ‒ User Trends and off-Label Prescribing for Weight Loss
Aurélie Mailhac et al. · Clinical Epidemiology · 2024
DOI 10.2147/clep.s456170
cross-sectional · n=91626Cited 47×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- The proportion of new users of semaglutide (Ozempic ® ) with a record of type 2 diabetes (T2D) declined from 99% in 2018 to only 67% in 2022, before increasing again to 87% in 2023.Moderate
- Most initiators of semaglutide (Ozempic ® ) with T2D had suboptimal glucose control, with 83% having an HbA1c ≥ 48 mmol/mol.Moderate
Related findings · Energy balance
- Achieving a total body weight loss of 10-15% (or >10-15 kg) through Total Diet Replacement (TDR) induces remission of Type 2 Diabetes in individuals with short-duration disease.Strong
- Bariatric surgery is superior to medical management alone for inducing significant long-term weight loss, remission of type 2 diabetes, and reduction in mortality for patients with BMI ≥ 40 or ≥ 35 with comorbidities.Strong
- Achieving type 2 diabetes remission requires significant weight loss (≥15 kg) via major caloric restriction, independent of macronutrient composition.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →